Safety, Tolerability, and Efficacy of Darexaban (YM150) in Patients With Acute Coronary Syndrome - RUBY -1


Darexaban is a novel oral factor Xa inhibitor, and has been shown to be effective in the treatment of venous thromboembolism (VTE). The current trial was a phase II trial designed to evaluate the safety and tolerability of different doses and dose regimens of darexaban on top of standard treatment (aspirin with or without clopidogrel) in the secondary prevention of ischemic vascular events in patients with recent acute coronary syndrome (ACS).